
IMMUPHARMA PLC — Investor Relations & Filings
ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| IMM initiatesIND-Enabling Program for Kapiglucagon | 2026-05-05 | English | |
| Holding(s) in Company | 2026-04-10 | English | |
| Chairman’s Open Letter to Shareholders | 2026-04-09 | English | |
| P140 Program Update | 2026-03-27 | English | |
| Result of WRAP Retail Offer and TVR | 2026-03-23 | English | |
| Publication of Circular | 2026-03-19 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
11 filings
| |||||
| 41263686 | IMM initiatesIND-Enabling Program for Kapiglucagon | 2026-05-05 | English | ||
| 33983950 | Holding(s) in Company | 2026-04-10 | English | ||
| 33900873 | Chairman’s Open Letter to Shareholders | 2026-04-09 | English | ||
| 33055396 | P140 Program Update | 2026-03-27 | English | ||
| 33011258 | Result of WRAP Retail Offer and TVR | 2026-03-23 | English | ||
| 32984423 | Publication of Circular | 2026-03-19 | English | ||
| 32970895 | ‘Investor Meet Company’ presentation on 20 March | 2026-03-18 | English | ||
| 32961838 | WRAP Retail Offer for up to £1.5 million | 2026-03-17 | English | ||
| 32961765 | P140 Update; Fundraise, Related Party Transaction | 2026-03-17 | English | ||
| 34555267 | Holding(s) in Company | 2026-01-06 | English | ||
| 12168492 | Attending JPMorgan Conference & Biotech Showcase | 2026-01-06 | English | ||
|
2025
4 filings
| |||||
| 8553183 | Corporate Update | 2025-11-24 | English | ||
| 8070439 | Holding(s) in Company | 2025-11-04 | English | ||
| 11397824 | IMMUPHARMA ATTENDING BIO-EUROPE | 2025-10-27 | English | ||
| 8037729 | Launch of Website; Corporate Update | 2025-10-23 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for IMMUPHARMA PLC, but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
R&G PharmaStudies Co., Ltd.
Full-service CRO providing clinical research solutions for …
|
301333 | CN | Professional, scientific and te… |
|
RHYTHM BIOSCIENCES LIMITED
Develops blood-based diagnostic technology for early colore…
|
RHY | AU | Professional, scientific and te… |
|
ROKIT HEALTHCARE Inc.
Develops an AI-powered organ regeneration platform using 4D…
|
376900 | KR | Professional, scientific and te… |
|
ROQUEFORT THERAPEUTICS PLC
Biotechnology company developing medicines for therapy-resi…
|
ROQ | GB | Professional, scientific and te… |
|
Royal Lifescience Corp.
Researches, develops, and commercializes specialized produc…
|
— | CA | Professional, scientific and te… |
|
RYVU Therapeutics S.A.
Clinical-stage company developing novel small molecule ther…
|
RVU | PL | Professional, scientific and te… |
|
Safe Supply Streaming Co. Ltd.
Provides advanced drug detection technology to prevent fent…
|
SPLY | CA | Professional, scientific and te… |
|
Sai Life Sciences Limited
Full-service CRO-CDMO for small molecule discovery, develop…
|
SAILIFE | IN | Professional, scientific and te… |
|
Salarius Pharmaceuticals, Inc.
Clinical-stage biopharmaceutical company developing therapi…
|
SLRX | US | Professional, scientific and te… |
|
SaltX Technology Holding B
Develops electrification and carbon capture technology for …
|
SALT | SE | Professional, scientific and te… |
IMMUPHARMA PLC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/7703/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=7703 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=7703 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=7703 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 7703}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for IMMUPHARMA PLC (id: 7703)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.